Einträge von Wicki, Andreas auf dem Publikationsserver

Rentsch, Cyrill A. , Thalmann, George N., Lucca, Ilaria, Kwiatkowski, Maciej, Wirth, Grégory J., Strebel, Räto T., Engeler, Daniel, Pedrazzini, Augusto, Hüttenbrink, Clemens, Schultze-Seemann, Wolfgang, Torpai, Raimund, Bubendorf, Lukas, Wicki, Andreas , Roth, Beat, Bosshard, Piet , Püschel, Heike, Boll, Daniel T., Hefermehl, Lukas, Roghmann, Florian, Gierth, Michael, Ribi, Karin , Schäfer, Simon und Hayoz, Stefanie (2022) A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. European Urology Oncology 5 (2), S. 195-202. Volltext nicht vorhanden.

Al-Batran, Salah-Eddin, Pauligk, Claudia, Hofheinz, Ralf, Lorenzen, Sylvie, Wicki, Andreas, Siebenhuener, Alexander Rheinhard, Schenk, Michael, Welslau, Manfred, Heuer, Vera, Goekkurt, Eray, Schmalenberg, Harald, Thuss-Patience, Peter C., Waberer, Lisa, Talbot, Jonathan, Goetze, Thorsten Oliver und Homann, Nils (2019) Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. Journal of Clinical Oncology 37 (15_sup), TPS4142-TPS4142. Volltext nicht vorhanden.